Fitch rates Wyeth notes A-

Fitch Ratings said it has assigned A- ratings to Wyeth's public issuance of $1 billion 5½% senior unsecured notes due 2016 and $500 million 6% senior unsecured notes due 2036.

The outlook is negative.

Other ratings include the A- issuer default rating and the F-2 commercial paper rating.

Wyeth's rating reflects strong operational performance, driven by its human pharmaceutical portfolio including the key products Protonix, Effexor, Prevnar, Enbrel and Zosyn, Fitch said.

The outlook is negative primarily due to continued exposure to Pondimin/Redux product liability, which has pressured cash flow generation since 2000, Fitch said.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.